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OBJECTIVES We sought to assess the variability of results obtained with thallium scintigraphy as a method
for tracking the extent of myocardial ischemia in medically refractory patients with angina
who are not suitable for coronary artery bypass graft surgery or percutaneous transluminal
coronary angioplasty.
BACKGROUND New therapies are being evaluated for patients with “no option” angina in whom medical
therapy has failed. Nuclear techniques, like thallium scintigraphy, are used in multicenter
trials to evaluate whether such therapies improve myocardial perfusion. However, the
variability of test results is unknown in this patient group in a multicenter study.
METHODS The Angina Treatments: Lasers And Normal Therapies In Comparison (ATLANTIC)
study was a randomized trial of transmyocardial laser revascularization (n 5 182). Patients
underwent dipyridamole thallium stress tests at baseline and 3, 6 and 12 months after
enrollment. The control group (n 5 90) was treated with constant medical therapy during the
study and is a relevant group to investigate test variability. Test variability over time was
quantified by the mean absolute change in the percentage of reversible perfusion defects
between baseline and follow-up.
RESULTS Baseline percent myocardium with ischemia averaged 17.0 6 13.7% and did not change
during follow-up. However, variations in the percent myocardium with reversible perfusion
defects over time amounted to an average of 6 to 8 percentage points, or 43% to 55% of the
baseline value. Only ;13% of this variability was attributable to variability in image
reconstruction and analysis.
CONCLUSIONS As demonstrated in the ATLANTIC study, percent myocardial ischemia in control subjects
receiving constant medical therapy varied in individual patients by an average of ;50%. This
may limit the utility of thallium scintigraphy to detect improved myocardial perfusion over
time in response to therapy. (J Am Coll Cardiol 2001;38:1033–9) © 2001 by the American
College of Cardiology
Angiogenic growth factor therapies (1) and transmyocardial
revascularization (TMR) (2–5) are being investigated for
treating patients with otherwise untreatable, medically re-
fractory angina (“no option” patients). The goal of these
therapies is to relieve symptoms by improving blood flow to
ischemic regions through induction of new blood vessel
growth. Although symptom relief and improved quality of
life and exercise tolerance are important therapeutic goals,
investigators have sought objective evidence of improved
myocardial perfusion, as seen in animal models of chronic
ischemia (6), using nuclear techniques such as thallium
scintigraphy (7–9). However, the variability of myocardial
perfusion defects assessed by such techniques in the target
patient population has not been determined within the
context of a multicenter study (10).
The Angina Treatments: Lasers And Normal Therapy In
Comparison (ATLANTIC) study (3) was a multicenter,
prospective, randomized study comparing TMR plus con-
tinued medical therapy with continued medical therapy
alone in otherwise untreatable patients with refractory
angina. Dipyridamole thallium stress tests performed at
baseline and 3, 6 and 12 months after study entry showed no
significant change in either group from baseline at any time
point in the percent myocardium exhibiting reversible (isch-
emic) defects. However, the standard deviation of the mean
percentage point change of ischemic myocardium in both
groups was relatively large, almost equaling the mean
baseline value of this variable. When focusing on the control
group, whose results were expected to be reasonably consis-
tent from one test to the next, this observation suggests that
test results may vary significantly in individual patients over
the study period. This raises questions as to the consistency
of the amount of ischemia present in these patients and
the variability inherent in the dipyridamole thallium stress
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testing over time, which has never been assessed in a
quantitative fashion in the context of a multicenter study
over a relatively long time frame. Previous efforts to examine
the variability of thallium scintigraphic results are limited to
evaluations performed at single centers with small numbers
of patients over short follow-up periods (11–14). Further-
more, these studies were performed in patients with routine
coronary artery disease (i.e., patients encountered more
commonly in daily practice with fewer and more discrete
coronary lesions), so that the results may not apply to the
“no option” patients being targeted for angiogenic therapies.
To address these questions, we assessed the variability of
test results over time in the control subjects of the ATLAN-
TIC study. This is an appropriate population in which to
address the question of test result consistency, because these
patients are fully representative of those being targeted for
angiogenic therapies, and because the patients were fol-
lowed for one year without any other interventions or
significant changes in medical therapy.
METHODS
The ATLANTIC study. The ATLANTIC study inclu-
sion and exclusion criteria and results have been presented
previously (3). Briefly, this was a 16-site, prospective,
randomized study that enrolled 182 subjects who provided
written, informed consent, with medically refractory class
III or IV angina deemed untreatable by coronary artery
bypass graft surgery (CABG) or percutaneous transluminal
coronary angioplasty (PTCA) and with an ejection fraction
$30%. Ninety-two subjects underwent TMR plus contin-
ued maximal antianginal therapy (TMR1MEDs), and 90
subjects received just continued medical therapy (MEDs
only). Subjects were followed for one year (no cross over),
and they continued treatment with the maximal anti-
anginal medical regimen. Subjects receiving TMR 1
MEDs demonstrated significant improvements in angina,
exercise tolerance and quality of life, whereas subjects
treated with MEDs only showed little change in any of
these variables.
Thallium scintigraphy. An experienced core laboratory
was used to standardize the procedures. Core laboratory
representatives visited the sites to review the protocol and
standardize acquisition variables. The collimator was set at
low energy and high resolution. The matrix size was set at
64 3 64 pixels; the zoom was set at 1:1.5; the number of
angles was 32 over a 180° range; the dwell time was set at
60 s; and the center of rotation and uniformity corrections
were applied during acquisition without attenuation correc-
tion. Drinks containing caffeine, sublingual and oral nitro-
glycerin and aminophylline were all withheld on the morn-
ing of the study. Repeat studies were performed at the same
time of day and on the same scanner as baseline studies. A
standard dipyridamole dose (0.14 mg/kg body weight per
min for 4 min, 0.056 mg/kg) and a standard thallium dose
(2.5 to 3.0 mCi initially, with an additional 1 mCi for
re-injection) were used. Raw data were sent to the core
laboratory for image reconstruction and analysis. Image
reconstruction was accomplished using SMV commercial
software (GE/SMV America, Twinsburg, Ohio), which
included correction for patient motion, Wiener filtering of
the projection data and filtered backprojection using a ramp
filter. The images were re-oriented for short-axis alignment.
The Stanford University bull’s-eye protocol was used to
create polar maps and quantitative analysis of activity
distribution (15,16).
The maps were compared with gender-specific normal
maps derived from stress/redistribution thallium studies in
28 men and 40 women. Two types of polar map quantitative
analyses were performed. In the first analysis, pixel intensi-
ties .2 SD below the normal mean value were considered as
abnormal. The image was analyzed pixel by pixel to deter-
mine the percentage of pixels with a reversible perfusion
defect (normal flow at rest and abnormal flow during stress,
ischemic), a fixed defect (abnormal flow at rest and stress,
infarct) or normal flow.
In the second analysis, an ischemic score was calculated by
weighting the abnormal pixel count by the severity of the
perfusion defect on the stress image. Each pixel was as-
signed a grade as follows: 0 when the pixel intensity was
within 2 SD of normal; 0.5 when the pixel intensity was $2
and ,3 SD below normal; 0.75 when the pixel intensity was
$3 and ,4 SDs below normal; and 1.0 when the pixel
intensity was $4 SD below normal. The total ischemic
score was the sum of the individual pixel scores; ischemic
and infarct-related pixels (based on the previous definition)
were summed separately.
The reproducibility of core laboratory procedures was
assessed by complete reprocessing of 15 randomly chosen
studies, one from all but one of the participating centers.
These scans were sent from the sites on four occasions
distributed over a one-year period to the core laboratory
under different identification numbers and were analyzed
along with all other scans without previous knowledge of
the core laboratory.
Thallium scan results: variability analysis. The main
analysis performed to assess test variability is illustrated in
Figure 1. In this example, the changes in the percent
myocardium with a reversible perfusion defect (which we
will define as “ischemia” in the present study) from baseline
Abbreviations and Acronyms
ANOVA 5 analysis of variance
ATLANTIC 5 Angina Treatments: Lasers And Normal
Therapies In Comparison study
CABG 5 coronary artery bypass graft surgery
MEDs 5 continued maximal antianginal therapy
PTCA 5 percutaneous transluminal coronary
angioplasty
SAQ 5 Seattle Angina Questionnaire
TMR 5 transmyocardial revascularization
VI 5 variability index
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were 210, 110 and 15 percentage points at the three
follow-up studies, so that the average change was only ;1.7
percentage points, ,10% of the baseline value of 25%.
However, the variation from test to test is large, so taking a
simple mean value obscures random fluctuations in the
results. Accordingly, it is more appropriate to quantify
variability based on the mean absolute change from baseline,
as suggested in a previous study (13).
VI 5 SO
i51
3 UIB 2 IiUDY3
where VI is the variability index; the subscript B designates
the baseline study; i indicates from 1 to 3 (corresponding to
the three follow-up studies); and I is the variable being used
to quantify the extent of the myocardial perfusion defect.
Variables that will be discussed include percent myocardium
with a reversible perfusion defect, percent myocardium with
a fixed perfusion defect and the total ischemic score. For
example, in Figure 1, the mean VI equals ;8 percentage
points ([10 1 10 1 5]/3), which amounts to 32% (i.e., 8/25)
of the baseline value. Values of VI were determined for all
subjects and were expressed in absolute percentage points.
All data are expressed as the mean value 6 SD. Com-
parisons between results obtained at baseline and follow-up
studies were compared with repeated measures analysis of
variance (ANOVA). Specific paired observations were com-
pared with the paired t test. A p value ,0.05 was considered
statistically significant.
RESULTS
Patient group. The baseline characteristics of the control
group (MEDs only) of the ATLANTIC study are summa-
rized in Table 1. The subjects were predominately men in
their mid-60s, with a high prevalence of cardiovascular risk
factors; most had a history of myocardial infarction and had
undergone at least one previous CABG or PTCA, or both.
Ejection fraction was well preserved, but exercise tolerance
was poor. The results from the Seattle Angina Question-
naire (SAQ) indicated a poor quality of life (each SAQ
index ranges from 0 to 100, with 100 indicating the best
quality of life) (17).
During the one-year follow-up period, there were nine
deaths in the MEDs-only group (10% mortality rate): seven
deaths due to cardiac causes and two of unknown causes.
Seven subjects withdrew from the study, and there were
several missed visits, which lowered the number of available
studies. If all available data are included, baseline and
three-month scans were available from 60 subjects, baseline
and six-month scans from 64 subjects and baseline and
12-month scans from 56 subjects. Scans were available from
47 subjects at all four time points.
It is important to point out that detailed analyses showed
that in subjects receiving MEDs only who completed the
study, there were no new Q wave myocardial infarctions,
and cardiovascular medication use did not change signifi-
cantly during the follow-up period (3).
Thallium stress test variability. A scattergram showing
the percent myocardial ischemia at baseline versus the
percent ischemia at three months (n 5 60) is shown in
Figure 2A. Although there is a statistically significant linear
relationship (solid line, y 5 0.7x 1 5.3; p , 0.001), the data
are scattered widely around both the regression line and the
line of identity (dashed line); both the correlation coefficient
(r2 5 0.43) and concordance correlation coefficient (rc 5
0.70) (14) were relatively low, indicating a high degree of
variation from one test to the other. These same data,
Figure 1. Variability of test results was quantified by the variability index
(VI), which was the mean value of the absolute change from baseline
percent myocardial ischemia.
Table 1. Baseline Characteristics of Subjects Receiving Medical
Therapy Only (n 5 90)
Age (years) 65 (36–78)
Gender
Female 7 (8%)
Male 83 (92%)
Diabetes 31 (34%)
Hypertension 79 (88%)
Hyperlipidemia 81 (90%)
History of smoking (any) 73 (81%)
Family history of CAD 70 (78%)
Previous MI 62 (69%)
Previous interventions
None 6 (7%)
CABG only 27 (30%)
PTCA only 8 (9%)
CABG and PTCA 49 (54%)
Baseline CCSAS
Class III 36 (40%)
Class IV 54 (60%)
Baseline EF (%) 45 (31–68)
Baseline ETT (s) 381 (89–747)
Baseline SAQ
Angina frequency 20 (0–80)
Angina stability 50 (0–100)
Physical limitation 31 (0–64)
Disease perception 25 (0–75)
Treatment satisfaction 63 (13–100)
Data are presented as the median value (range) or number (%) of subjects.
CABG 5 coronary artery bypass graft surgery; CAD 5 coronary artery disease;
CCSAS 5 Canadian Cardiovascular Society Angina Score; EF 5 ejection fraction;
ETT 5 exercise tolerance test; MI 5 myocardial infarction; PTCA 5 percutaneous
transluminal coronary angioplasty; SAQ 5 Seattle Angina Questionnaire (17).
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plotted to show the change in percent ischemia (three-
month minus baseline) as a function of baseline ischemia
(Fig. 2B), show that the points scattered approximately
equally above and below the line of 0 change with a
relatively large degree of variability. The scattergrams and
quantitative results were similar for the 6- and 12-month
follow-up data.
For the 60 patients who had scans at baseline and at three
months of follow-up, the mean percent myocardial ischemia
at baseline was 17 6 16% (Fig. 3). The mean (6SD)
percent ischemia on the follow-up scans was nearly the
same, indicating that the mean change was ;0 percentage
points. However, if the mean absolute change is analyzed
instead of the mean change in percent ischemia, there is a
variation of ;9 percentage points in the test results (Fig. 3,
cross-hatched bars). This degree of variability, which
amounts to ;50% of the baseline amount of ischemia, was
similar for the subset of 64 patients having scans at baseline
and six months, as well as for the 56 patients having scans
at baseline and 12 months (Fig. 3). Repeated measures
ANOVA showed that there was no change in the mean
percent myocardial ischemia over time (p 5 NS). Further-
more, the interclass correlation coefficient determined from
this ANOVA was 0.75, which confirms a relatively weak
correlation between the serial test results. Similarly, the
value of VI between follow-up visits did not vary signifi-
cantly (p 5 NS).
For illustrative purposes, the results from individual
subjects shown in Figure 4 graphically illustrate the varia-
tions associated with different VI values; percent ischemia
and infarction are both shown. A subject having a VI similar
to the mean value for the group (9.5) is shown in Figure 4A;
a subject with a smaller than average VI (5.0) is shown in
Figure 4B; and a subject with a worse than average VI (20.0)
is shown in Figure 4C. Dramatic changes—both improve-
ments and worsening—are illustrated in these examples.
It is also evident in these examples that the percent
myocardium with a fixed perfusion deficit also varies signif-
icantly over time. For the 47 subjects with data at all time
points, the percent myocardium with a fixed perfusion
defect (“infarction”) at baseline was 14.1 6 10.8%, with an
overall variability index of 6.9 6 4.8 percentage points, or
;50% of the baseline value. Furthermore, if fixed and
reversible defects are considered (i.e., added) together in this
same group of subjects, the mean percent myocardium with
abnormal perfusion is 29.7 6 16.9% at baseline. This
variable also did not vary significantly at any follow-up time
point (p 5 NS by repeated measures ANOVA), and the
Figure 2. (A) Scattergram showing baseline versus three-month percent
ischemia for 60 subjects in the ATLANTIC study; solid line 5 line of
regression; dashed line 5 line of identity. (B) Change in percent ischemia
between baseline and three months as a function of baseline percent
myocardial ischemia for the same subjects. The points scattered approxi-
mately equally above and below the horizontal line of 0 change with large
variability. The dashed line shows the maximal possible reduction in
ischemia for a given baseline value. See text for further details.
Figure 3. Mean percent myocardial ischemia at baseline and follow-up at
specified times (paired analysis) and mean absolute change in perfusion.
Although it is evident that the mean change in perfusion is negligible at
each time, the mean absolute change in perfusion amounts to ;50% of the
baseline value. Mean values 6 SD are shown.
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overall variability index was 9.4 6 4.7 percentage points,
which amounted to ;30% of the baseline value.
The total ischemia score (see Methods) was also subjected
to a similar analysis. The baseline value of this unitless
variable was 390 6 266, and the respective overall variability
index derived from the 47 subjects having data at all time
points was 154 6 92, ;39% of the baseline value.
Thus, the large variability in the results was not limited to
the quantification of percent ischemia, per se, but was also
apparent in several other indexes of myocardial ischemia.
Reproducibility of image reconstruction and analysis.
Fifteen scans selected at random were sent to the core
laboratory under different identification numbers and were
analyzed four times without the core laboratory’s knowledge
that they were duplicates. The results of this analysis
showed that, with few exceptions, the results obtained on
subsequent repeat analysis were very similar to those of the
original analysis. The regression line between the first
analysis and the three subsequent analyses was indistin-
guishable from the line of identity (y 5 1.0x 2 0.9, r2 5
0.94, p , 0.0001). The variability index (refer to the
equation in the Methods) amounted to only 2.9 6 2.0
percentage points. Thus, the variability of image reconstruc-
tion contributed to the test’s variability, but this was a minor
component.
Stratification of subjects by the amount of ischemia at
baseline. To test whether variability is less in subjects with
more ischemia, data from the 56 subjects in the MEDs-only
group with test results at baseline and 12 months were
stratified according to the percent ischemia at baseline and
classified into three groups of an approximately equal
number of subjects, as shown in Figure 5A. There was a
slight increase in the overall VI from ;5 percentage points
in the group with ,7% baseline ischemia to a maximum of
;11 points in the group with .25% baseline ischemia.
However, because VI (absolute percentage points) increased
far less than the mean value of baseline ischemia in the
different groups, the percent variability decreased substan-
tially as the amount of baseline ischemia increased. This
suggests that the test could be more reliable in detecting
changes in perfusion in subjects with a greater amount of
baseline ischemia.
To test this hypothesis, data from subjects treated with
TMR in ATLANTIC (TMR 1 MEDs) were studied. The
baseline characteristics of the 92 original TMR 1 MEDs
subjects were similar to those of the MEDs-only group (3).
After accounting for mortality, subject withdrawal and
missed visits, 58 of these subjects had scans at both baseline
and 12 months. If data from these subjects were stratified
according to the same criteria as described earlier, the
subjects with the greatest amount of ischemia at baseline
had a substantial and highly statistically significant decrease
in percent ischemia 12 months after TMR (Fig. 5B).
Patients in the middle group showed no change, and
patients with little baseline ischemia showed a small increase
in the perfusion defect. These findings initially suggested
that in the subgroup with the greatest amount of baseline
ischemia, TMR might have resulted in significantly im-
proved perfusion. However, data from the 56 subjects in the
MEDs-only group with scans at both baseline and 12
months analyzed in this same way (Fig. 5C) revealed the
same trends (even with regard to statistical significance).
This behavior is an example of the statistical phenomenon
of “regression to the mean” when random noise is superim-
posed on baseline and follow-up “true” test values.
Figure 4. Examples of percent myocardium with fixed and reversible
perfusion defects, which varies as a function of time in medically treated
subjects. (A) A subject with a variability index (VI) of 9.5 (refer to the
equation in Methods), approximately equal to mean VI for the entire group
of subjects. (B) A subject with a VI of 5.0, significantly less than the mean
VI for the group. (C) A subject with a VI of 20, significantly greater than
the mean VI for the group. Note that dramatic improvements (complete
resolution) in the amount of ischemia were observed sometimes.
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DISCUSSION
Our analysis indicates that, as implemented in the AT-
LANTIC study, the results of dipyridamole thallium stress
testing yielded quantitative assessments of myocardial isch-
emia that were variable from one test to another. The
magnitude of the variability amounted to approximately half
of the mean baseline value of ischemia. Such variability was
observed with several different variables used to quantify the
ischemic burden. Stratification of subjects according to the
degree of baseline ischemia did not improve the situation.
Rather, regression to the mean value on follow-up studies
was observed—that is, scans with low amounts of ischemia
at baseline increased during follow-up, whereas scans with
high amounts of ischemia at baseline decreased.
Comparison with previous studies. Variability of nuclear
stress test results has been examined previously in a few
single-center studies in small numbers of patients (11–13).
In one of these studies (13), 16 stable subjects studied
prospectively (one month between studies) and data from 23
subjects examined retrospectively (up to 13 months between
studies) demonstrated a low mean absolute change of 4.5%
(identical to the VI used in the present study) and a high
concordance correlation coefficient of 0.94 (a statistical
index of the tests’ similarity) (14) between percent ischemia
determined from polar map analysis on baseline and
follow-up studies; values of both indexes are substantially
better than achieved in the present study. The investigators
concluded that in stable patients, the percent hypoperfused
myocardium is reproducible over the course of a year.
Conclusions provided by other studies have been similar
(11,12).
The present study is different from previous studies in
that it is the first to test variability in a prospective,
multicenter trial, analyzed in a completely blinded manner,
from a significantly large number of subjects, over a one-
year period, with four tests being performed over the
follow-up period. Unlike earlier studies, the subjects in this
study are fully representative of those being targeted for
angiogenic therapy (Table 1), with medically refractory
angina, angiographically documented, severe coronary artery
disease that cannot be revascularized and a high incidence of
previous myocardial infarction.
Potential sources of variability. Many potential sources of
variability could contribute to the present findings. The
conditions of the patients could have changed significantly
over time. Subtle changes in medications could have oc-
curred, which were not detected during follow-up. To
standardize the degree of intersubject and intrasubject
stress, the protocol indicated that the tests be performed at
the same time of day, on the same scanner; that certain
medications be withheld before the study; and that standard
doses of dipyridamole and thallium be administered. How-
ever, deviations from these protocols could have occurred.
Records documenting the physiologic response to dipyrid-
amole (i.e., changes in heart rate and systemic blood
pressure) would have been helpful, but were not reported to
the core laboratory. Intrinsic variability in test results could
Figure 5. (A) Results (mean 6 SD) stratified according to percent baseline
ischemia. Test variability, indexed by variability index (VI) (refer to the
equation in Methods) increases as baseline ischemia increases, so that VI as
a proportion of baseline ischemia decreases. (B) Baseline and 12-month
follow-up thallium results from subjects who had transmyocardial laser
revascularization (TMR) in the ATLANTIC study, stratified according to
percent baseline ischemia. Although the data in B suggest TMR may
improve myocardial perfusion in subjects with a greater amount of baseline
ischemia, data from the ATLANTIC subjects in the continued maximal
anti-anginal therapy (MEDs)-only group (C) exhibit the same trends. This
suggests a “regression to the mean” phenomenon, as discussed in the text.
The p values were derived from paired t tests.
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also be a factor. The data collected within the context of the
ATLANTIC study were not sufficient to define the major
source(s) of test result variation. The contribution of varia-
tions in the techniques used to reconstruct scans at the core
laboratory were investigated and shown to contribute only a
small amount to overall test variability, however. It is
possible that more careful attention to technical details,
which is difficult in practice within the context of large-
scale, multicenter studies, could reduce test result variability,
rendering the test more useful in detecting blood flow
changes. Future studies could also include pilot investiga-
tions to determine the specific degree of variability at the
centers involved in order to make more appropriate calcu-
lations of sample size.
Conclusions. Irrespective of whether the observed variabil-
ity reflects changes in the patients’ status over the follow-up
period or technical limitations related to how dipyridamole
thallium was implemented in the ATLANTIC study, the
present findings provide important and practical informa-
tion for future studies. Several therapies are under develop-
ment for “no option” patients with medically refractory
angina. The present results suggest that if nuclear scintig-
raphy is employed in this patient population to quantify
changes in myocardial perfusion in multicenter studies, it is
important to ensure adequate test reproducibility by dem-
onstrating sufficiently low variability and by including
enough subjects in the statistical analysis. These results
should be considered to apply to the “no option” group of
patients with severe coronary artery disease evaluated in the
ATLANTIC study, and not necessarily to the patients
encountered more commonly in daily practice with fewer
and more discrete coronary lesions. The results (Figs.
4A and C) further indicate that anecdotal reports of
dramatic improvements in myocardial perfusion after TMR
or angiogenic therapy should be avoided. Unless adequate
test variability is documented and is sufficiently low, similar
dramatic improvements can be observed in untreated pa-
tients over the course of a one-year follow-up period.
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